Patients with SNCA p.G51D mutations show clinical signs of early-onset rapidly progressive levodopa responsive parkinsonism, but can also present with pyramidal signs and severe cognitive impairment and hallucinations (Lesage et al., 2013; Tokutake et al., 2014; Kiely et al., 2015). Here, SNCA is linked to Parkinsonism.